Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer

Thomas Powles; Laurence Albiges; Michael Staehler; Karim Bensalah; Saeed Dabestani; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Sergio Fernández-Pello; Rana Tahbaz; Alessandro VOLPE; Börje Ljungberg; Axel Bex

doi:10.1016/j.eururo.2017.11.016

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer

Thomas Powles
, Laurence Albiges
, Michael Staehler
, Karim Bensalah
, Saeed Dabestani
, Rachel H Giles
, Fabian Hofmann
, Milan Hora
, Markus A Kuczyk
, Thomas B Lam
, Lorenzo Marconi
, Axel S Merseburger
, Sergio Fernández-Pello
, Rana Tahbaz
, Alessandro VOLPE
, Börje Ljungberg
, Axel Bex

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline standard of care for this disease and have implications for the selection of subsequent therapies. For this reason the European Association of Urology RCC guidelines have been updated.

Lingua originale	Inglese
Rivista	EUROPEAN UROLOGY
DOI	https://doi.org/10.1016/j.eururo.2017.11.016
Stato di pubblicazione	Pubblicato - 2017

Keywords

European Association of Urology guidelines
Ipilimumab
Nivolumab
Renal cell carcinoma

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.eururo.2017.11.016

http://hdl.handle.net/11579/104667

Altri file e collegamenti

handle

Cita questo

Powles, T., Albiges, L., Staehler, M., Bensalah, K., Dabestani, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T. B., Marconi, L., Merseburger, A. S., Fernández-Pello, S., Tahbaz, R., VOLPE, A., Ljungberg, B., & Bex, A. (2017). Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. EUROPEAN UROLOGY. https://doi.org/10.1016/j.eururo.2017.11.016

@article{0c0a15eb186349d8b71f6aa4cd04bf85,

title = "Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer",

abstract = "The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-na{\"i}ve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline standard of care for this disease and have implications for the selection of subsequent therapies. For this reason the European Association of Urology RCC guidelines have been updated.",

keywords = "European Association of Urology guidelines, Ipilimumab, Nivolumab, Renal cell carcinoma, European Association of Urology guidelines, Ipilimumab, Nivolumab, Renal cell carcinoma",

author = "Thomas Powles and Laurence Albiges and Michael Staehler and Karim Bensalah and Saeed Dabestani and Giles, \{Rachel H\} and Fabian Hofmann and Milan Hora and Kuczyk, \{Markus A\} and Lam, \{Thomas B\} and Lorenzo Marconi and Merseburger, \{Axel S\} and Sergio Fern{\'a}ndez-Pello and Rana Tahbaz and Alessandro VOLPE and B{\"o}rje Ljungberg and Axel Bex",

note = "Publisher Copyright: {\textcopyright} 2017 European Association of Urology",

year = "2017",

doi = "10.1016/j.eururo.2017.11.016",

language = "English",

journal = "EUROPEAN UROLOGY",

issn = "1873-7560",

}

Powles, T, Albiges, L, Staehler, M, Bensalah, K, Dabestani, S, Giles, RH, Hofmann, F, Hora, M, Kuczyk, MA, Lam, TB, Marconi, L, Merseburger, AS, Fernández-Pello, S, Tahbaz, R, VOLPE, A, Ljungberg, B & Bex, A 2017, 'Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer', EUROPEAN UROLOGY. https://doi.org/10.1016/j.eururo.2017.11.016

TY - JOUR

T1 - Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer

AU - Powles, Thomas

AU - Albiges, Laurence

AU - Staehler, Michael

AU - Bensalah, Karim

AU - Dabestani, Saeed

AU - Giles, Rachel H

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus A

AU - Lam, Thomas B

AU - Marconi, Lorenzo

AU - Merseburger, Axel S

AU - Fernández-Pello, Sergio

AU - Tahbaz, Rana

AU - VOLPE, Alessandro

AU - Ljungberg, Börje

AU - Bex, Axel

PY - 2017

Y1 - 2017

N2 - The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline standard of care for this disease and have implications for the selection of subsequent therapies. For this reason the European Association of Urology RCC guidelines have been updated.

AB - The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the combination of ipilimumab and nivolumab when compared with the previous standard of care in first-line metastatic/advanced clear cell renal cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline standard of care for this disease and have implications for the selection of subsequent therapies. For this reason the European Association of Urology RCC guidelines have been updated.

KW - European Association of Urology guidelines

KW - Ipilimumab

KW - Nivolumab

KW - Renal cell carcinoma

KW - European Association of Urology guidelines

KW - Ipilimumab

KW - Nivolumab

KW - Renal cell carcinoma

UR - https://iris.uniupo.it/handle/11579/104667

U2 - 10.1016/j.eururo.2017.11.016

DO - 10.1016/j.eururo.2017.11.016

M3 - Article

SN - 1873-7560

JO - EUROPEAN UROLOGY

JF - EUROPEAN UROLOGY

ER -

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo